SODIUM NITRITE injection, solution United States - English - NLM (National Library of Medicine)

sodium nitrite injection, solution

hope pharmaceuticals - sodium nitrite (unii: m0kg633d4f) (nitrite ion - unii:j39976l608) - sodium nitrite 30 mg in 1 ml - sodium nitrite injection, an antidote, is indicated for sequential use with sodium thiosulfate for the treatment of acute cyanide poisoning that is judged to be serious or life-threatening. when the diagnosis of cyanide poisoning is uncertain, the potentially life-threatening risks associated with sodium nitrite injection should be carefully weighed against the potential benefits, especially if the patient is not in extremis. none risk summary life-sustaining therapy should not be withheld. cyanide poisoning is a medical emergency in pregnancy, which can be fatal for the pregnant woman and fetus if left untreated (see clinical considerations). therefore, if a pregnant woman has known or suspected cyanide poisoning, sodium nitrite injection for sequential use with sodium thiosulfate injection is recommended [see indications and usage (1)]. there are no available data on sodium nitrite injection use in pregnant women to establish a drug-associated risk for major birth defects, miscarriage, or adverse maternal

SODIUM THIOSULFATE injection, solution United States - English - NLM (National Library of Medicine)

sodium thiosulfate injection, solution

hope pharmaceuticals - sodium thiosulfate (unii: hx1032v43m) (thiosulfate ion - unii:llt6xv39py) - sodium thiosulfate 250 mg in 1 ml - sodium thiosulfate injection is indicated for sequential use with sodium nitrite for the treatment of acute cyanide poisoning that is judged to be serious or life-threatening. when the diagnosis of cyanide poisoning is uncertain, the potential risks associated with sodium thiosulfate injection should be carefully weighed against the potential benefits, especially if the patient is not in extremis. none risk summary there are no available data on sodium thiosulfate injection use in pregnant women to establish a drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes. there are risks to the pregnant woman and fetus associated with untreated cyanide poisoning (see clinical considerations). therefore, if a pregnant woman has known or suspected cyanide poisoning, sodium thiosulfate injection for sequential use with sodium nitrite is recommended [see indications and usage (1)] . in published animal studies, no evidence of embryotoxicity or malformations was reported when sodium thiosulfate was administered during organogenesis to pregnant mice, rats, hamsters, or rats at 0.2 to 0.9 times the human daily dose of 12.5 g for cyanide poisoning. the studies did not test doses that were comparable to the human dose for cyanide poisoning (see data). the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the us general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. clinical considerations disease-associated maternal and/or embryo/fetal risk cyanide readily crosses the placenta. cyanide poisoning is a medical emergency in pregnancy, which can be fatal for the pregnant woman and fetus if left untreated. life-sustaining therapy should not be withheld due to pregnancy. data animal data: no malformations or evidence of embryo-fetal toxicity were noted when pregnant mice, rats, hamsters, or rabbits were administered oral doses of sodium thiosulfate of up to 550, 400, 400, or 580 mg/kg, respectively during organogenesis (0.2, 0.3, 0.26, and 0.9 times the human dose of 12.5 g/60 kg person for cyanide poisoning based on body surface area). published studies suggest that treatment with sodium thiosulfate ameliorates the teratogenic effects of maternal cyanide poisoning in hamsters. risk summary there are no data on the presence of sodium thiosulfate in human or animal milk, the effects on the breastfed infant, or the effects on milk production. cyanide and thiocyanate (which is formed when sodium thiosulfate combines with cyanide) are present in human milk. because of the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended during treatment with sodium thiosulfate injection. there are no data to determine when breastfeeding may be safely restarted following the administration of sodium thiosulfate injection. there are case reports in the medical literature of sodium nitrite in conjunction with sodium thiosulfate being administered to pediatric patients with cyanide poisoning; however, there have been no clinical studies to evaluate the safety or efficacy of sodium thiosulfate in the pediatric population. as for adult patients, dosing recommendations for pediatric patients have been based on theoretical calculations of antidote detoxifying potential, extrapolation from animal experiments, and a small number of human case reports. sodium thiosulfate is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. sodium thiosulfate is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

SODIUM CHLORIDE injection, solution United States - English - NLM (National Library of Medicine)

sodium chloride injection, solution

american regent, inc. - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698) - sodium chloride 9 mg in 1 ml - intravenous solutions containing sodium chloride are indicated for parenteral replenishment of fluid and sodium chloride as required by the clinical condition of the patient. none known.

SODIUM CHLORIDE injection, solution United States - English - NLM (National Library of Medicine)

sodium chloride injection, solution

laboratorios grifols sa - sodium chloride (unii: 451w47iq8x) (chloride ion - unii:q32zn48698, sodium cation - unii:lyr4m0nh37) - sodium chloride 9 g in 1000 ml - sodium chloride injection, usp is indicated as a source of water and electrolytes. 0.9% sodium chloride injection, usp is also indicated for use as a priming solution in hemodialysis procedures. none known.

SODIUM CHLORIDE injection United States - English - NLM (National Library of Medicine)

sodium chloride injection

liebel-flarsheim company llc - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37) - sodium chloride .9 mg in 1 ml - - 125 ml syringe:  sodium chloride injection usp 0.9% is indicated for use in flushing compatible contrast agents through liebel-flarsheim intravenous administration sets into indwelling intravascular access devices only when delivered by the following liebel-flarsheim power injectors: angiomat® , illumena® , illumena® néo, ct9000® , ct9000® adv, optistat® , optivantage® and optistar elite. none risk summary administration of sodium chloride injection usp 0.9% is not known to cause major birth defects, miscarriage or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with sodium chloride injection usp 0.9.% all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. risk summary appropriate administration of sodium chloride injection usp 0.9% is not known to cause ha

CLASTEON 800mg film-coated Tablets Malta - English - Medicines Authority

clasteon 800mg film-coated tablets

beacon pharmaceuticals limited the bower 4 roundwood avenue, stockley park, heathrow, ub11 1af, united kingdom - clodronate sodium, anhydrous - film-coated tablet - clodronate sodium, anhydrous 800 milligram(s) - drugs for treatment of bone diseases

CLASTEON 800mg film-coated Tablets Malta - English - Medicines Authority

clasteon 800mg film-coated tablets

athlone pharmaceuticals limited ballymurray co. roscommon f42 ew02 , ireland - clodronate sodium, anhydrous - film-coated tablet - clodronate sodium, anhydrous 800 mg - drugs for treatment of bone diseases

SODIUM CHLORIDE injection, solution, concentrate United States - English - NLM (National Library of Medicine)

sodium chloride injection, solution, concentrate

hospira, inc. - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698) - sodium chloride 234 mg in 1 ml - 23.4% sodium chloride injection, usp is indicated for use as an electrolyte replenisher in parenteral fluid therapy. it serves as an additive for total parenteral nutrition (tpn) and as an additive for carbohydrate containing i.v. fluids. 23.4% sodium chloride injection, usp additive solution is contraindicated in patients with hypernatremia or fluid retention.

SODIUM BICARBONATE 500 MG Israel - English - Ministry of Health

sodium bicarbonate 500 mg

rekah pharmaceutical industry ltd, israel - sodium bicarbonate - tablets - sodium bicarbonate 500 mg - sodium bicarbonate - sodium bicarbonate - antacid.

SODIUM CHLORIDE 0.45 % INJECTION Israel - English - Ministry of Health

sodium chloride 0.45 % injection

teva medical marketing ltd. - sodium chloride - solution for infusion - sodium chloride 450 mg / 100 ml - sodium chloride - sodium chloride - supply of water and electrolytes.